Transcat (NASDAQ:TRNS) Stock Rating Raised to “Outperform” at Oppenheimer

Transcat (NASDAQ:TRNS) was upgraded by research analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a report released on Wednesday, Marketbeat Ratings reports. The firm presently has a $115.00 target price on the scientific and technical instruments company’s stock. Oppenheimer‘s target price would indicate a potential upside of 28.46% from the company’s current price.

TRNS has been the topic of a number of other reports. Northland Securities raised shares of Transcat from a “market perform” rating to an “outperform” rating and set a $95.00 target price on the stock in a research report on Wednesday, October 21st. CJS Securities initiated coverage on shares of Transcat in a research report on Tuesday, October 27th. They issued an “outperform” rating and a $115.00 price target for the company. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Transcat in a research note on Tuesday, August 25th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Transcat currently has a consensus rating of “Hold” and an average price target of $108.33.

Transcat Price Performance

Shares of NASDAQ TRNS opened at $89.52 on Wednesday. The stock’s 50-day simple moving average is $86.10 and its 200-day simple moving average is $81.83. The firm has a market capitalization of $840.59 million, a PE ratio of 241.95 and a beta of 0.61. Transcat has a fifty-two week low of $50.23 and a fifty-two week high of $100.00. The company has a debt-to-equity ratio of 0.36, a quick ratio of 2.11 and a current ratio of 2.49.

Transcat (NASDAQ:TRNS) last announced its quarterly earnings results on Tuesday, November 3rd. The scientific and technical instruments company reported $0.64 EPS for the quarter, beating the consensus estimate of $0.45 by $0.19. Transcat had a net margin of 0.99% and a return on equity of 5.56%. The company had revenue of $97.09 million for the quarter, compared to analyst estimates of $92.46 million. As a group, equities research analysts forecast that Transcat will post 1.79 EPS for the current fiscal year.

Insider Activity at Transcat

In other news, Director Christopher P. Gillette sold 504 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $94.23, for a total transaction of $47,491.92. Following the transaction, the director directly owned 200 shares in the company, valued at approximately $18,846. This trade represents a 71.59% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Craig Cairns bought 1,050 shares of the business’s stock in a transaction dated Thursday, August 6th. The stock was acquired at an average cost of $93.97 per share, for a total transaction of $98,668.50. Following the completion of the acquisition, the director directly owned 1,480 shares in the company, valued at approximately $139,075.60. This trade represents a 244.19% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 1.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of TRNS. Integrated Wealth Concepts LLC acquired a new stake in shares of Transcat during the second quarter worth $32,000. Persistent Asset Partners Ltd acquired a new position in Transcat in the 2nd quarter valued at $52,000. GAMMA Investing LLC raised its position in Transcat by 133.6% during the 3rd quarter. GAMMA Investing LLC now owns 1,030 shares of the scientific and technical instruments company’s stock worth $91,000 after buying an additional 589 shares during the last quarter. Squarepoint Ops LLC raised its position in Transcat by 9.0% during the 2nd quarter. Squarepoint Ops LLC now owns 8,794 shares of the scientific and technical instruments company’s stock worth $816,000 after buying an additional 728 shares during the last quarter. Finally, Corient Private Wealth LP raised its position in Transcat by 9.1% during the 2nd quarter. Corient Private Wealth LP now owns 9,509 shares of the scientific and technical instruments company’s stock worth $882,000 after buying an additional 791 shares during the last quarter. 98.34% of the stock is currently owned by institutional investors and hedge funds.

Key Transcat News

Here are the key news stories impacting Transcat this week:

• Positive Sentiment: Transcat earned $0.64 per share, up from $0.44 a year earlier and above consensus estimates of roughly $0.42–$0.45. Revenue was $97.09 million, topping the $92.46 million estimate. Zacks earnings report
• Positive Sentiment: The company raised its fiscal 2027 outlook for service organic growth to the low double digits and is targeting at least 100 basis points of service gross-margin expansion in the second half. That outlook points to continued demand and improving service profitability. Outlook update
• Positive Sentiment: Management characterized the quarter as strong, citing double-digit organic service revenue growth and significant service gross-margin expansion. Transcat fiscal second-quarter results

About Transcat

Transcat, Inc (NASDAQ: TRNS) provides calibration, compliance, and measurement services for organizations that rely on accurate test and measurement equipment. The company supports customers in regulated industries, including life sciences, aerospace and defense, energy, manufacturing, and other industrial markets.

Its service offerings include laboratory and onsite calibration, repair, validation, and asset-management services. Transcat calibrates a broad range of equipment used to measure temperature, pressure, electrical and electronic properties, radio frequency signals, dimensional characteristics, and other technical parameters.